Research database

HyMedPoly - Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications

Duration:
49 months (2018)
Principal investigator(s):
Project type:
UE-funded research - H2020 - Excellent Science - Marie Curie
Funding body:
COMMISSIONE EUROPEA
Project identification number:
H2020-MSCA-ITN-2014

Abstract

There is a general consensus that biomedical polymers of natural and synthetic origin should and will play a very important role in the development of new therapeutic strategies to treat diseases. Due to resistance of bacteria to drugs, infection has become one of the toughest problems in the medical world as there are hardly any effective antibiotics left in the fight against many pathogens. This project aims to develop new therapies through a new combination of technology (a) development of new hybrid polymers with antibacterial functionality,(b) introduction of inhibitors that can permanently deactivate bacteriological proteases and (c) new formulations of bioactive ceramics and glasses that have specific charge potential to prevent bacterial growth. The challenge is to develop new medical polymers that have an intrinsic antibacterial functionality to achieve clinical effectiveness in the field

Structures

Partners

  • COMMISSIONE EUROPEA

Budget

Total cost: € 3,918,054.96
Total contribution: € 3,918,054.96
PoliTo total cost: € 1,032,245.28
PoliTo contribution: € 722,091.80